ONCAlert | Upfront Therapy for mRCC

Biomarker-Driven Lung Cancer VIEW MORE >>

Entrectinib led to clinically meaningful responses in patients with NTRK fusion-positive solid tumors, according to results from a pooled analysis of the phase I ALKA-372-001, the phase I STARTRK-1, and the phase II STARTRK-2 studies published in The Lancet Oncology.

Latest JournalAll Journals >>

Copyright © TargetedOnc 2020 Intellisphere, LLC. All Rights Reserved.